louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04134338: Effect of Surgical Wound Infection on Health
Official title: Effect of Surgical Wound Infection on Health of Women
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Infection
Lead sponsor: Aljazeera Hospital
Sponsor class: OTHER
Collaborators: name: Cairo University
First posted: 2019-10-22
Enrollment: 100
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 42
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: women who experienced wound infection

Brief summary: A surgical site infection (SSI) is an infection that occurs after surgery in the part of the body

Detailed description: Morbidity and mortality were associated with increase of surgical site infections (SSIs).Besides, it was a financial burden and negatively impact of SSIs on patient quality of life (QoL).

Eligibility criteria: Inclusion Criteria:

* wound who had infection post surgery

Exclusion Criteria:

* women who had no infection

Primary outcomes:
measure: What is the effect of surgical site infection on health care cost
timeFrame: within a month
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Kasralainy Hospital
Study officials:
affiliation: Algezeera hospitaland National Research Centre ,Egypt
name: Mahmoud Alalfy, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT06987838: Effect of Virtual Reality on Prostaglandin Levels in Adolescent Females With Primary Dysmenorrhea
Official title: Effect of Virtual Reality on Prostaglandin Levels in Adolescent Females With Primary Dysmenorrhea: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Primary Dysmenorrhea
Lead sponsor: Benha National University
Sponsor class: OTHER
First posted: 2025-05-23
Enrollment: 50
Sex: FEMALE
Minimum age (years): 17
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will be conducted to study the effect of virtual reality therapy on prostaglandin levels in adolescent females with primary dysmenorrhea.

Detailed description: Primary dysmenorrhea is thought to be caused by excessive levels of prostaglandins, which are hormones that stimulate the uterus to contract during menstruation and childbirth, Treatment must be tailored to individual patient symptoms. Pharmacologic management with non-steroidal anti-inflammatory medications and/or combined hormonal contraceptives is most common. Heat therapy, exercise, vitamins and dietary supplements have limited evidence and can be offered for patients seeking non-pharmacologic adjunctive or alternative options. Greater awareness for both health-care providers and patients allow for early intervention to reduce impact on quality of life and life course potential. The significance of this study to assess the effect of virtual reality therapy on primary dysmenorrhea.

Eligibility criteria: Inclusion Criteria:

* Age 17- 21 years old.
* The body mass index (BMI) \< 30 kg/m2.
* Unmarried females.
* Females with dysmenorrhea pain.
* Females with regular menstrual cycles.
* Females with normal gynecology.

Exclusion Criteria:

* Have a pathological disease related to reproduction.
* Students who use analgesic drugs for 3 months/3 menstrual cycles.
* Students with menstrual pain secondary to diagnosed organic or inflammatory causes.

Primary outcomes:
measure: Visual Analogue Scale (VAS)
timeFrame: 12 weeks
measure: Assessment of Prostaglandin Levels
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Misr University for Science and Technology
Study officials:
affiliation: Lecturer, Benha National University
name: Sally Mohamed Saeed, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Lecturer, Al Hayah University
name: Malak Adel El Mahdy, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Lecturer, Misr University for Science and Technology
name: Sarah Abdullah Mohamed Elsamahy, PhD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Lecturer, Misr University for Science and Technology
name: Samah Mahmoud Ahmed sheha, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Lecturer, Al Hayah University
name: Naglaa fathey moustafa, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01304238: Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II
Official title: Systematische Dokumentation Von Patienten Mit Akutem HIT-Verdacht
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute HIT II (Heparin-induced Thrombocytopenia Type II)
Keywords: Retrospective evaluation of patients with acute Heparin-induced Thrombocytopenia type II treated with Fondaparinux
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2011-02-25
Enrollment: 195
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Hospitalized patients with HIT

Brief summary: The purpose of this retrospective registry is to collect data about patients with acute HIT II (Heparin-induced Thrombocytopenia type II) which were treated with Lepirudin, Danaparoid, Argatroban or Fondaparinux. It is a main objective of this registry to mirror the daily routine in this indication in Germany.


Eligibility criteria: Inclusion Criteria:

* Acute HIT II (Heparin-induced Thrombocytopenia type II), 4T-Score
* Treatment of HIT with Lepirudin, Danaparoid, Argatroban or Fondaparinux

Exclusion Criteria:

-

Primary outcomes:
measure: Number of Participants Diagnosed With Thrombosis and/or Pulmonary Embolism After the Occurrence of HIT II
timeFrame: 19 January 2005 to 25 October 2009
Secondary outcomes:
measure: Number of Participants Diagnosed With Bleeding After the Occurrence of HIT II
timeFrame: 19 January 2005 to 25 October 2009
measure: Number of Participants With Fatal Complications After the Occurrence of HIT II
timeFrame: 19 January 2005 to 25 October 2009
measure: Number of Participants Who Underwent Amputation After the Occurrence of HIT II
timeFrame: 19 January 2005 to 25 October 2009
measure: Number of Participants Who Were Diagnosed With Thrombocytopenia (Recurrent of Persistent) After the Occurrence of HIT II
timeFrame: 19 January 2005 to 25 October 2009
measure: Number of Participants Who Experienced Skin Changes (Erythema and Necrosis) After the Occurrence of HIT II
timeFrame: 19 January 2005 to 25 October 2009
Other outcomes:
Locations:
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
citation: Schindewolf M, Steindl J, Beyer-Westendorf J, Schellong S, Dohmen PM, Brachmann J, Madlener K, Potzsch B, Klamroth R, Hankowitz J, Banik N, Eberle S, Muller MM, Kropff S, Lindhoff-Last E. Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia. J Am Coll Cardiol. 2017 Nov 28;70(21):2636-2648. doi: 10.1016/j.jacc.2017.09.1099.
Clinical trial NCT03639038: Tuberculosis Diagnosis by Flow Cytometry
Official title: Reagent Evaluation Plan: Tuberculosis Diagnosis by Flow Cytometry (Project Orion)
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Tuberculosis
Lead sponsor: University of Alabama at Birmingham
Sponsor class: OTHER
First posted: 2018-08-20
Enrollment: 0
Sex: ALL
Minimum age (years): 5
Maximum age (years): 100
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Participants will be selected on a first come, first serve basis at TB clinics in MOH District clinics in Lusaka. The participants will include both confirmed TB patients as well as presumptive TB patients. All participants should not have started anti-TB treatment (ATT) prior to enrollment or be less than five days from treatment start.

Brief summary: Tuberculosis and HIV continue to be major public health problems in resource constrained settings like Zambia. Zambia is among the top 30 highest burden countries globally. The major drivers of TB in the Africa region is the HIV epidemic. Inadequate TB diagnostic tools with failure to make a timely diagnosis and start appropriate treatment are the major impediments to TB control in Zambia and globally.

Detailed description: Project Orion is focused on utilizing Flow Cytometry Technology to screen and diagnose tuberculosis. There are two assays being tested under this Project:

1. Activated TB assay for differentiation of latent and active TB infection using blood samples and
2. Direct TB assay (DTA) for rapid detection and DST of Mycobacterium tuberculosis (Mtb) using sputum specimens.)

Eligibility criteria: Inclusion Criteria:

* Presumptive TB patients (patients recommended for tuberculosis diagnostic testing and not on ATT)
* Patients with multi-drug resistant TB (MDR-TB)
* Paediatric patients (\< 15 years old)
* Patients suspected of extra-pulmonary tuberculosis
* Patients with TB/HIV co-infection

Exclusion Criteria:

* Unable/unwilling to sign Informed consent

Primary outcomes:
measure: ATB assay for differentiation of latent and active TB infection using Blood samples
timeFrame: The duration of this project is 9 months.
measure: DTB assay for rapid detection and drug sensitivity testing of Mtb using sputum specimens
timeFrame: The duration of this project is 9 months.
Secondary outcomes:
Other outcomes:
Locations:
city: Lusaka
country: Zambia
facility: Center for Infectious Disease Research in Zambia (CIDRZ)
Study officials:
affiliation: Center for Infectious Disease Research in Zambia
name: Monde Muyoyeta, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00186238: High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
Official title: High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Multiple Myeloma
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2005-09-16
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To assess the role of autologous hematopoietic cell rescue in the treatment of multiple myeloma.

Detailed description: To assess the toxicity and efficacy of sequentially administered high dose cyclophosphamide and VP-16 followed by total body irradiation or BCNU and high dose mephalan and autologous stem cell rescue in the treatment of multiple myeloma.

Eligibility criteria: Inclusion Criteria:- received cytoreduction prior to transplant

* adequate organ function Exclusion Criteria:- previous transplant
* smoldering MM or benign monoclonal gammopathy

Primary outcomes:
measure: Toxicity and efficacy of sequentially administered high dose chemotherapy and autologous hematopoietic cell transplantation
timeFrame: Patients will have a daily CBC with platelet count, and chemistries until engraftment, then as indicated clinically. Chest x-rays will be done weekly until engraftment, then as indicated clinically. Patients will be restaged for abnormal proteins (SPIE)
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Sally Arai
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02482038: Geko Venous Leg Ulcer Study
Official title: A Single Centre Open Label Pilot Study Measuring Lower Limb Blood Flow in Patients With Venous Leg Ulcers Using the Geko™ T-2 or gekoTM Plus [R-2] Neuromuscular Electro Stimulation Device
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Venous Leg Ulcer
Lead sponsor: Firstkind Ltd
Sponsor class: INDUSTRY
First posted: 2015-06-25
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This study is designed to look at the effect of the geko device on the circulation in lower limbs of participants with venous leg ulcers.


Eligibility criteria: Inclusion Criteria:

1. Age ≥ 18 years
2. Intact healthy skin at the site of device application
3. Able to understand the Patient Information Sheet
4. Willing to give informed consent
5. Willing to follow the requirements of the protocol
6. Subjects who had a chronic venous leg ulcer (i.e. CEAP classification of C6 1) greater than 2 cm2 and less than 10 cm in maximum diameter,
7. ABPI of 0.8 or greater

Exclusion Criteria:

1. History of significant haematological disorders or DVT with the preceding six months
2. Pregnant
3. Pacemakers or implantable defibrillators
4. Use of any other neuro-modulation device
5. Current use of TENS in pelvic region, back or legs
6. Use of investigational drug or device within the past 4 weeks that may interfere with this study
7. Recent surgery (such as abdominal, gynaecological, hip or knee replacement)
8. Recent trauma to the lower limbs
9. Size of leg incompatible with the geko™ device.
10. Chronic obesity (BMI \> 34)
11. Any medication deemed to be significant by the Investigator
12. Subjects who had an index venous leg ulcer greater in maximum diameter than 10cm in any one dimension
13. Diabetic subjects with advanced small vessel disease

Primary outcomes:
measure: Ultra sound measurements of haemodynamics
timeFrame: 10mins
Secondary outcomes:
measure: Adverse event rate
timeFrame: 2 hrs
measure: patient rated tolerability
timeFrame: 2 hrs
Other outcomes:
Locations:
city: Ealing
country: United Kingdom
facility: Ealing Hospital
state: Middlesex
Study officials:
References:
Clinical trial NCT01175538: Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis
Official title: Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis: an Open Labeled Randomized Controlled Trial of Lactulose Versus no Lactulose
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Hepatic Encephalopathy
Keywords: Hepatic encephalopathy
Lactulose
Lead sponsor: Govind Ballabh Pant Hospital
Sponsor class: OTHER_GOV
First posted: 2010-08-05
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: To assess the effects of lactulose for the prevention of first episode of altered sensorium (hepatic encephalopathy, primary prophylaxis) in patients with cirrhosis.

Detailed description: Development of hepatic encephalopathy in a patient with cirrhosis is associated with poor survival rate of 10-70% at one year depending upon hepatic and renal functions. Treating patients to prevent development of first episode of hepatic encephalopathy is classified as primary prophylaxis of hepatic encephalopathy and preventing recurrence of hepatic encephalopathy in patients who had previous episode of hepatic encephalopathy is secondary prophylaxis of hepatic encephalopathy

Eligibility criteria: Inclusion Criteria:

* cirrhotic patients(18-70yrs) who never had encephalopathy

Exclusion Criteria:

* history of taking lactulose in the past 6 weeks
* alcohol intake during the past 6 weeks
* hepatocellular carcinoma
* previous TIPS or shunt surgery
* significant co morbid illness such as heart, respiratory, or renal failure
* neurologic diseases such as alzheimer's disease, parkinson's disease and nonhepatic metabolic encephalopathies.
* patients on psychoactive drugs such as antidepressants or sedatives
* who restarted alcohol during follow up

Primary outcomes:
measure: prevention of first episode of hepatic encephalopathy
timeFrame: 6 months
Secondary outcomes:
measure: Side effects to lactulose and mortality
timeFrame: 6 months
Other outcomes:
Locations:
city: New Delhi
country: India
facility: G B Pant Hospital
state: Delhi
Study officials:
affiliation: G B Pant Hospital New Delhi 110002
name: Barjesh C Sharma, MD,DM
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05394038: Rapid Diagnosis of Patients With Chest Pain During the Covid-19 Outbreak (My-ABCDE)
Official title: Application of Rapid Risk Stratification for Patients Presenting With Chest Pain in the Emergency Department During the Covid-19 Outbreak in Shanghai, China.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chest Pain
Lead sponsor: Shanghai 10th People's Hospital
Sponsor class: OTHER
First posted: 2022-05-27
Enrollment: 2218
Sex: ALL
Minimum age (years): 14
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients who came to the hospital with chest tightness and chest pain during Covid-19.

Brief summary: During the outbreak of COVID-19, among patients with chest tightness and chest pain as the main symptoms in major medical institutions in Shanghai, China, the past medical history and rapid testing were used to quickly identify the risk stratification of the patients.

Detailed description: During the outbreak of COVID-19, among patients with chest tightness and chest pain as the main symptoms in major medical institutions in Shanghai, China, the past medical history and rapid testing were used to quickly identify the risk stratification of the patients. Past medical history collection includes diabetes, hypertension, coronary atherosclerotic heart disease, percutaneous coronary stent implantation, etc. Rapid detection includes rapid myocardial markers, coagulation function, electrocardiogram, chest CT, etc. Risk stratification in the shortest possible time to reduce the time patients spend congregating in hospitals and reduce unnecessary contact to reduce the risk of Covid-19 infection.

Eligibility criteria: Inclusion Criteria:

* All patients who came to the hospital with chest tightness and chest pain during Covid-19.

Exclusion Criteria:

* None.

Primary outcomes:
measure: Diagnosis time
timeFrame: 1 week
Secondary outcomes:
measure: Diagnostic accuracy
timeFrame: 1week
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Tenth People's Hospital
state: Shanghai
Study officials:
affiliation: Tongji University
name: Yawei Xu, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT01590238: Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM)
Official title: Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Alopecia
Keywords: alopecia
Lead sponsor: The New York Eye & Ear Infirmary
Sponsor class: OTHER
First posted: 2012-05-02
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Clinical alopecia occurs due to miniaturization of the hair shafts as well as loss of active production of hair shafts. PRFM has been shown to induce dermal angiogenesis, and anecdotal findings of improvement of hair appearance after PRFM injection in the scalp suggest that PRFM may play a role in the treatment of thinning hair. Patients will be treated on a monthly basis with intradermal injections of autologous PRFM for 3 months. Changes in hair density will be assessed by comparing pre- and post-treatment photographs and non-invasive measurements of hair density at 1, 2, 3, 4 and 6 months after initial treatment.


Eligibility criteria: Inclusion Criteria:

* age 18- 75 years old
* frontal and/or crown alopecia

Exclusion Criteria:

* bleeding disorder

Primary outcomes:
measure: Hair Density Change After Three Treatments
timeFrame: 6 months after initial visit
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: The New York Eye & Ear Infirmary
state: New York
Study officials:
References:
Clinical trial NCT06761638: Comparative Impact of RAST and TST for Improving Motor Functions in Stroke Patients
Official title: Comparative Impact of Rhythmic Auditory Stimulation Therapy and Task Specific Training for Improving Motor Functions in Stroke Patients
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Stroke
Lead sponsor: Superior University
Sponsor class: OTHER
First posted: 2025-01-07
Enrollment: 40
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study evaluates the effectiveness of Rhythmic Auditory Stimulation (RAS) therapy versus Task-Specific Training (TST) in enhancing motor function recovery in stroke patients. RAS uses rhythmic cues to aid movement synchronization, while TST focuses on practicing daily tasks to improve functional ability. In a randomized clinical trial, participants were assigned to either RAS or TST groups, with both receiving structured sessions over several weeks.


Eligibility criteria: Inclusion Criteria:

* Male and female patients diagnosed with stroke
* Age 40-80 years (46)
* Patients having first ever stroke occurrence
* Moderate motor function impairments (47)
* Patients able to follow instruction

Exclusion Criteria:

* Patients with severe motor impairments
* Patients who had cognitive impairments
* Patients having other neurological conditions and musculoskeletal disorders
* Patients having history of surgery

Primary outcomes:
measure: Modified Barthel index
timeFrame: 12 Months
measure: Goniometer
timeFrame: 12 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Azra Naheed Medical College, Superior University
state: Punjab
Study officials:
References:
Clinical trial NCT02657538: Validation of Near-infrared Light Transillumination for Interproximal Enamel Caries Detection
Official title: Validation of Near-infrared Light Transillumination for Interproximal Enamel Caries Detection: A Clinical Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dental Caries
Keywords: Interproximal caries
Enamel caries
Caries detection
Caries diagnostics
Near-infrared light transillumination
DIAGNOcam
Lead sponsor: University of Bern
Sponsor class: OTHER
First posted: 2016-01-18
Enrollment: 35
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The aim of this study is to validate a near-infrared light transillumination device (DIAGNOcam, KaVo, Biberach, Germany) for interproximal enamel caries detection and compare it with the established diagnostic methods (visual examination and bitewing radiography). The aim is to avoid/reduce ionizing radiation for caries diagnostic purposes.


Eligibility criteria: Inclusion Criteria:

* ASA-Status 1
* Complete permanent dentition
* Bitewing radiography already existing (\< 4 months)
* Minimum of one cavitation-free approximal surface, symptomless, interproximal enamel or dentin caries lesion in the posterior teeth without restorations and/or sound tooth surface.

Exclusion Criteria:

* Children younger than 15 Years

Primary outcomes:
measure: Caries Extension According to Diagnocam Codes 0-4 (Intra- and Interrater-Reliability, Sensitivity and Specificity)
timeFrame: One year
Secondary outcomes:
measure: Lesion Activity
timeFrame: One year
Other outcomes:
Locations:
Study officials:
affiliation: Department of Preventive, Restorative and Pediatric Dentistry, University of Bern
name: Klaus W Neuhaus, PD
role: PRINCIPAL_INVESTIGATOR
References: